Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:03:25.236Z.
Calculation as of: 2026-10-06T16:03:25.236Z.
Quote observation: 2026-10-06T16:00:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
PE RATIO
N/A
Market Cap
$48.27M
PE Ratio
N/A
TTM Avg
43.98
3Y Avg
82.17
5Y Avg
82.17
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.20M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $44.35M | 8.79 | 6.98 | 6.98 | 6.98 |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.31M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.27M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $44.05M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | N/A | 7.83 | 14.59 | 14.59 |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.27M | N/A | 43.98 | 82.17 | 82.17 |
| Precipio, Inc. (PRPO)vs › | $41.92M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $48.66M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.16M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.93
Forward EPS (Est.)
$-0.89
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
